Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations.

Cancer research - 15 Sept 2021

Yenerall Paul, Kollipara Rahul K, Avila Kimberley, Peyton Michael, Eide Christopher A, Bottomly Daniel, McWeeney Shannon K, Liu Yan, Westover Kenneth D, Druker Brian J, Minna John D, Kittler Ralf

Abstract excerpt

Identifying resistance mutations in a drug target provides crucial information. Lentiviral transduction creates multiple types of mutations due to the error-prone nature of the HIV-1 reverse transcriptase (RT). Here we optimized and leveraged this property to identify drug resistance mutations, developing a technique we term LentiMutate. This technique was validated by identifying clinically relevant EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Drug Resistance, Neoplasm

Share to Gene Expression Regulation, Neoplastic

Share to Genetic Vectors

Share to Lentivirus

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 34301758
DOI: 10.1158/0008-5472.CAN-21-1153
PMCID: PMC8448967

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations.PMID 34301758Read ↗

An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents.Semantic proximity Read ↗

A method for screening and validation of resistant mutations against kinase inhibitors.Semantic proximity Read ↗

CRISPR-Cas9–mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracySemantic proximity Read ↗

Target Mutation-Driven Drug Discovery.Semantic proximity Read ↗

Systemic tumor-targeting gene drive vectors proactively eliminate drug resistance in solid tumorsSemantic proximity Read ↗

High-throughput screening using pseudotyped lentiviral particles: A strategy for the identification of HIV-1 inhibitors in a cell-based assaySemantic proximity Read ↗

Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies.Semantic proximity Read ↗

Lentiviral Transduction of P140K MGMT into Human CD34+ Hematopoietic Progenitors at Low Multiplicity of Infection Confers Significant Resistance to BG/BCNU and Allows Selection in VitroSemantic proximity Read ↗

A new system for parallel drug screening against multiple-resistant HIV mutants based on lentiviral self-inactivating (SIN) vectors and multi-colour analysesSemantic proximity Read ↗

Versatile Viral Vector Strategies for Postscreening Target Validation and RNAi ON-Target Control.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.